Artiva Biotherapeutics, Inc. (ARTV) intrinsic value & 10-year financials
Artiva Biotherapeutics, Inc. (ARTV) has a Graham intrinsic value of $562.19 per share. At $5.85 on Oct 17, 2026, the stock trades 99% below that value. Over the last 4 fiscal years revenue shrank 99.2% a year to $0, with an average return on invested capital of 80.2%.
- Graham intrinsic value
- $562.19
- Share price (Oct 17, 2026)
- $5.85
- Price vs Graham value
- 99% below
- Market cap
- $143.0M
- Revenue (FY2025)
- $0
- Revenue growth (4-yr CAGR)
- -99.2%
- ROIC (10-yr avg)
- 80.2%
- Free cash flow (FY2025)
- -$79.3M
ARTV 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$83.9M | -$3.43 | -$79.3M | — | -72.4% |
| FY2024 | $251.0K | -$65.4M | -$5.81 | -$55.7M | -26805.6% | 297.8% |
| FY2023 | $32.9M | -$28.7M | -$2.56 | -$50.7M | -93.2% | 15.2% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Artiva Biotherapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Artiva Biotherapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -18.1% ROIC.
Artiva Biotherapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Artiva Biotherapeutics, Inc. is modeled at -99.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $562.19 per share.